Meropenem is generally well tolerated. In clinical trials, adverse events lead to cessation of treatment in <1% of patients. Serious adverse events are rare.
Common Events: Local IV injection Site Reactions
: Inflammation, thrombophlebitis, pain.
Nausea, vomiting, diarrhea.
Reversible increases in serum transaminases, bilirubin, alkaline phosphatase and lactic dehydrogenase alone or in combination have been reported.
Uncommon Events (<1%): Systemic Allergic Reactions:
Systemic allergic reactions (hypersensitivity) may occur following administration of meropenem. These reactions may include angioedema and manifestations of anaphylaxis.
Rash, pruritus, urticaria, severe skin reactions e.g. erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis have been observed.
Pseudomembranous colitis, jaundice and hepatic failure have been reported but a casual link with meropenem has not been established.
Blood and Lymphatic System Disorders:
Eosinophilia, leukopenia, thrombocytopenia, neutropenia, agranulocytosis, hemolytic anemia has been observed very rarely. A positive direct or indirect Coomb's test may develop.
Cardiac failure has been reported but a causal link with Meropenem has not been established.
Central Nervous System:
Headache, paresthesia, delirium, hallucinations and convulsions has been reported but a causal link with meropenem has not been established.
Pneumonia and respiratory failure have been reported but a causal link with meropenem has not been established.
Body as a Whole:
Fever and septicemia have been reported but a causal link with meropenem has not been established.
Oral and vaginal candidiasis.